MA33190B1 - Composes pour le traitement de troubles metaboliques - Google Patents
Composes pour le traitement de troubles metaboliquesInfo
- Publication number
- MA33190B1 MA33190B1 MA34244A MA34244A MA33190B1 MA 33190 B1 MA33190 B1 MA 33190B1 MA 34244 A MA34244 A MA 34244A MA 34244 A MA34244 A MA 34244A MA 33190 B1 MA33190 B1 MA 33190B1
- Authority
- MA
- Morocco
- Prior art keywords
- metabolic disorders
- compounds
- treatment
- diabetes
- exhibit
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/63—One oxygen atom
- C07D213/64—One oxygen atom attached in position 2 or 6
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Abstract
L'invention concerne des composés thérapeutiques qui présentent une activité d'agonistes de GPR119 et sont utiles pour traiter des troubles métaboliques, y compris le diabète de type 2 (I).
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0904284.7A GB0904284D0 (en) | 2009-03-12 | 2009-03-12 | Compounds for the treatment of metabolic disorders |
PCT/GB2010/050440 WO2010103333A1 (fr) | 2009-03-12 | 2010-03-12 | Composés pour le traitement de troubles métaboliques |
Publications (1)
Publication Number | Publication Date |
---|---|
MA33190B1 true MA33190B1 (fr) | 2012-04-02 |
Family
ID=40600945
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA34244A MA33190B1 (fr) | 2009-03-12 | 2010-03-12 | Composes pour le traitement de troubles metaboliques |
Country Status (18)
Country | Link |
---|---|
US (1) | US20120077793A1 (fr) |
EP (1) | EP2406247A1 (fr) |
JP (1) | JP2012520282A (fr) |
KR (1) | KR20110133044A (fr) |
CN (1) | CN102348703A (fr) |
AU (1) | AU2010222671A1 (fr) |
BR (1) | BRPI1013245A2 (fr) |
CA (1) | CA2754709A1 (fr) |
CL (1) | CL2011002181A1 (fr) |
EA (1) | EA201190208A1 (fr) |
GB (1) | GB0904284D0 (fr) |
IL (1) | IL215049A0 (fr) |
MA (1) | MA33190B1 (fr) |
MX (1) | MX2011009490A (fr) |
PE (1) | PE20120657A1 (fr) |
SG (1) | SG174279A1 (fr) |
WO (1) | WO2010103333A1 (fr) |
ZA (1) | ZA201107445B (fr) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010149685A1 (fr) | 2009-06-24 | 2010-12-29 | Boehringer Ingelheim International Gmbh | Nouveaux composés, composition pharmaceutique et procédés s'y rapportant |
MX2011013648A (es) | 2009-06-24 | 2012-03-06 | Boehringer Ingelheim Int | Nuevos compuestos, composiciones farmaceuticas y metodos relacionados con ellos. |
JP2013522279A (ja) | 2010-03-18 | 2013-06-13 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 糖尿病及び関連状態の治療で用いるgpr119作動薬とddp−iv阻害薬リナグリプチンの組合せ |
WO2012066077A1 (fr) | 2010-11-18 | 2012-05-24 | Prosidion Limited | Dérivés 1,4 di substitués pyrolidine-3-yl-amine et leur utilisation pour le traitement de troubles métaboliques |
GB201114389D0 (en) | 2011-08-22 | 2011-10-05 | Prosidion Ltd | Novel compounds |
CA2836487A1 (fr) | 2011-06-09 | 2012-12-13 | Rhizen Pharmaceuticals Sa | Nouveaux composes utilises comme modulateurs de gpr-119 |
US8853239B2 (en) * | 2011-12-09 | 2014-10-07 | Boehringer Ingelheim International Gmbh | Compounds, pharmaceutical compositions and uses thereof |
AR091739A1 (es) | 2012-07-11 | 2015-02-25 | Elcelyx Therapeutics Inc | Composiciones y metodos para reducir el riesgo cardiometabolico |
KR101719321B1 (ko) * | 2016-03-31 | 2017-03-23 | 충남대학교산학협력단 | 3-(4-클로로페닐)벤조[4, 5]이미다조[2, 1-b]싸이아졸-6-카복실산을 포함하는 항비만 또는 항우울증 치료용 조성물 |
CN109053524A (zh) * | 2018-09-11 | 2018-12-21 | 山东谛爱生物技术有限公司 | 一种N-Boc-3-羟基氮杂环丁烷的制备方法 |
CN117279889A (zh) * | 2022-04-28 | 2023-12-22 | 深圳湾实验室 | 经取代的氟硫酸盐及其用途 |
Family Cites Families (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6100042A (en) | 1993-03-31 | 2000-08-08 | Cadus Pharmaceutical Corporation | Yeast cells engineered to produce pheromone system protein surrogates, and uses therefor |
GB9719496D0 (en) | 1997-09-13 | 1997-11-19 | Glaxo Group Ltd | G protien chimeras |
EP1123391A2 (fr) | 1998-09-01 | 2001-08-16 | BASF Aktiengesellschaft | Methodes permettant d'ameliorer la fonction des recepteurs heterologues couples a la proteine g |
US6221660B1 (en) | 1999-02-22 | 2001-04-24 | Synaptic Pharmaceutical Corporation | DNA encoding SNORF25 receptor |
MXPA05004890A (es) * | 2002-11-07 | 2005-07-22 | Merck & Co Inc | Derivados de fenilalanina como inhibidores de dipeptidilpeptidasa para el tratamiento o prevencion de diabetes. |
EP1711491A1 (fr) | 2003-12-24 | 2006-10-18 | Prosidion Limited | Derives heterocycliques utilises comme agonistes des recepteurs gpcr |
US8193359B2 (en) | 2004-12-24 | 2012-06-05 | Prosidion Limited | G-protein coupled receptor agonists |
KR20070091038A (ko) | 2004-12-24 | 2007-09-06 | 프로시디온 리미티드 | G-단백질 결합 수용체(gpr116) 효능제 및 비만 및당뇨병을 치료하기 위한 이의 용도 |
GB0428514D0 (en) | 2004-12-31 | 2005-02-09 | Prosidion Ltd | Compounds |
AU2006264651A1 (en) | 2005-06-30 | 2007-01-11 | Prosidion Limited | G-protein coupled receptor agonists |
EP1907384A2 (fr) | 2005-06-30 | 2008-04-09 | Prosidion Limited | Agonistes de gpcr |
US20100063081A1 (en) | 2005-06-30 | 2010-03-11 | Stuart Edward Bradly | CPCR Agonists |
JP5114395B2 (ja) | 2005-06-30 | 2013-01-09 | プロシディオン・リミテッド | Gpcrアゴニスト |
WO2007116229A1 (fr) | 2006-04-06 | 2007-10-18 | Prosidion Limited | Agonistes gpcr hétérocycliques |
GB0607196D0 (en) | 2006-04-11 | 2006-05-17 | Prosidion Ltd | G-protein coupled receptor agonists |
GB0610746D0 (en) | 2006-06-01 | 2006-07-12 | Prosidion Ltd | Method of treatment |
CN101657471B (zh) * | 2006-12-06 | 2013-07-03 | 史密丝克莱恩比彻姆公司 | 二环化合物及其作为抗糖尿病药的用途 |
PE20081849A1 (es) | 2007-01-04 | 2009-01-26 | Prosidion Ltd | Derivados de piperidin-4-il-propoxi-benzamida como agonistas de gpcr |
CA2674360A1 (fr) | 2007-01-04 | 2008-07-10 | Prosidion Limited | Agonistes de gpcr piperidiniques |
CL2008000018A1 (es) | 2007-01-04 | 2008-08-01 | Prosidion Ltd | Compuestos derivados de heterociclos de nitrogeno y oxigeno, agonistas de gpcr; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de la obesidad, diabetes, sindrome metabolico, hiperlipidemia, toleranci |
GB0700122D0 (en) | 2007-01-04 | 2007-02-14 | Prosidion Ltd | GPCR agonists |
PL2114933T3 (pl) | 2007-01-04 | 2012-02-29 | Prosidion Ltd | Piperydyny jako agoniści GPCR |
JP2010539152A (ja) | 2007-09-10 | 2010-12-16 | プロシディオン・リミテッド | 代謝障害の治療のための化合物 |
GB0720389D0 (en) | 2007-10-18 | 2008-11-12 | Prosidion Ltd | G-Protein Coupled Receptor Agonists |
CN101827958A (zh) | 2007-10-18 | 2010-09-08 | 日矿金属株式会社 | 金属包覆的聚酰亚胺复合体、该复合体的制造方法以及电子电路板的制造方法 |
CN101621337B (zh) | 2008-06-30 | 2013-08-07 | 华为技术有限公司 | 一种时延调节装置与方法 |
CA2728042A1 (fr) | 2008-07-10 | 2010-01-14 | Prosidion Limited | Agonistes des recepteurs couples aux proteines g (gpcr) piperidinyles |
GB0812641D0 (en) | 2008-07-10 | 2008-08-20 | Prosidion Ltd | Compounds |
JP2011527332A (ja) | 2008-07-10 | 2011-10-27 | プロシディオン・リミテッド | ピペリジンgpcr作動薬 |
GB0812648D0 (en) | 2008-07-10 | 2008-08-20 | Prosidion Ltd | Compounds |
-
2009
- 2009-03-12 GB GBGB0904284.7A patent/GB0904284D0/en not_active Ceased
-
2010
- 2010-03-12 EA EA201190208A patent/EA201190208A1/ru unknown
- 2010-03-12 KR KR1020117024018A patent/KR20110133044A/ko not_active Application Discontinuation
- 2010-03-12 JP JP2011553532A patent/JP2012520282A/ja active Pending
- 2010-03-12 EP EP10709925A patent/EP2406247A1/fr not_active Withdrawn
- 2010-03-12 PE PE2011001632A patent/PE20120657A1/es not_active Application Discontinuation
- 2010-03-12 AU AU2010222671A patent/AU2010222671A1/en not_active Abandoned
- 2010-03-12 CA CA2754709A patent/CA2754709A1/fr not_active Abandoned
- 2010-03-12 US US13/255,525 patent/US20120077793A1/en not_active Abandoned
- 2010-03-12 BR BRPI1013245A patent/BRPI1013245A2/pt not_active Application Discontinuation
- 2010-03-12 SG SG2011064441A patent/SG174279A1/en unknown
- 2010-03-12 CN CN2010800115541A patent/CN102348703A/zh active Pending
- 2010-03-12 MX MX2011009490A patent/MX2011009490A/es unknown
- 2010-03-12 WO PCT/GB2010/050440 patent/WO2010103333A1/fr active Application Filing
- 2010-03-12 MA MA34244A patent/MA33190B1/fr unknown
-
2011
- 2011-09-05 CL CL2011002181A patent/CL2011002181A1/es unknown
- 2011-09-08 IL IL215049A patent/IL215049A0/en unknown
- 2011-10-11 ZA ZA2011/07445A patent/ZA201107445B/en unknown
Also Published As
Publication number | Publication date |
---|---|
BRPI1013245A2 (pt) | 2016-04-05 |
AU2010222671A1 (en) | 2011-11-03 |
CL2011002181A1 (es) | 2012-05-04 |
WO2010103333A1 (fr) | 2010-09-16 |
MX2011009490A (es) | 2011-10-11 |
SG174279A1 (en) | 2011-10-28 |
CN102348703A (zh) | 2012-02-08 |
US20120077793A1 (en) | 2012-03-29 |
PE20120657A1 (es) | 2012-06-27 |
EP2406247A1 (fr) | 2012-01-18 |
ZA201107445B (en) | 2012-06-27 |
GB0904284D0 (en) | 2009-04-22 |
EA201190208A1 (ru) | 2012-04-30 |
CA2754709A1 (fr) | 2010-09-16 |
IL215049A0 (en) | 2011-11-30 |
JP2012520282A (ja) | 2012-09-06 |
KR20110133044A (ko) | 2011-12-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA33241B1 (fr) | Composes pour le traitement de troubles metaboliques | |
MA33190B1 (fr) | Composes pour le traitement de troubles metaboliques | |
MA33242B1 (fr) | Composes pour le traitement de troubles metaboliques | |
MX2009008159A (es) | Compuestos y composiciones como moduladores de la actividad de gpr119. | |
TN2010000122A1 (en) | Compounds and compositions as modulators of gpr119 activity | |
PL2134704T3 (pl) | Związki i kompozycje pełniące rolę modulatorów aktywności GPR119 | |
TW200612926A (en) | Compounds and compositions as ppar modulators | |
MX2009006339A (es) | Compuestos y composiciones como inhibidores de actividad de receptor 1 de cannabinoide. | |
EA201001329A1 (ru) | Соединения и композиции в качестве модуляторов активности gpr119 | |
MX2007009356A (es) | Compuestos y composiciones como moduladores de ppar. | |
TNSN08373A1 (en) | Azolopyrimidines as inhibitors of cannabinoid 1 activity | |
MY145070A (en) | Imidazolothiazole compounds for the treatment of disease | |
TW200600505A (en) | Compounds and compositions as ppar modulators | |
EA201071245A1 (ru) | Новые терапевтические подходы для лечения болезни альцгеймера и связанных нарушений посредством модулирования реакции клеток на стресс | |
TNSN07161A1 (en) | Compounds and compositions as inhibitors of cannabinoid receptor 1 activity | |
EA201001332A1 (ru) | Соединения и композиции в качестве модуляторов активности gpr119 | |
EA201100138A1 (ru) | 4-феноксиметилпиперидины в качестве модуляторов активности gpr119 | |
EA200801897A1 (ru) | Ингибиторы mnk2 на основе 8-гетероарилпурина для лечения метаболических нарушений | |
EA201000603A1 (ru) | ПРИМЕНЕНИЕ АНТИТЕЛ К TrkB ДЛЯ ЛЕЧЕНИЯ РЕСПИРАТОРНЫХ НАРУШЕНИЙ | |
UA109878C2 (uk) | Похідні ізохінолінону, фармацевтична композиція на їх основі (варіанти) та спосіб лікування захворювань (варіанти) | |
GB0625648D0 (en) | Compounds | |
MX2007010560A (es) | Roflumilast para el tratamiento de diabetes mellitus. | |
EA201101475A1 (ru) | Способы применения рецептора gpr119 для идентификации соединений, которые можно использовать для увеличения костной массы субъекта | |
EA201001330A1 (ru) | Соединения и композиции в качестве модуляторов активности gpr119 | |
IN2012DN02471A (fr) |